It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
More than half of biomedical findings cannot be reproduced – we urgently need a way to ensure that discoveries are properly checked
One goal of scientific publication is to share results in enough detail to allow other research teams to reproduce them and build on them. However, many recent reports have raised the alarm that a shocking amount of the published literature in fields ranging from cancer biology to psychology is not reproducible.
Pharmaceuticals company Bayer, for example, recently revealed that it fails to replicate about two-thirds of published studies identifying possible drug targets (Nature Reviews Drug Discovery, vol 10, p 712).
Bayer's rival Amgen reported an even higher rate of failure - over the past decade its oncology and haematology researchers could not replicate 47 of 53 highly promising results they examined (Nature, vol 483, p 531). Because drug companies scour the scientific literature for promising leads, this is a good way to estimate how much biomedical research cannot be replicated. The answer: the majority.
The reasons for this are myriad. The natural world is complex, and experimental methods do not always capture all possible variables. Funding is limited and the need to publish quickly is increasing.
There are human factors, too. The pressure to cut corners, to see what one wants and believes to be true, to extract a positive outcome from months or years of hard work, and the impossibility of being an expert in all the experimental techniques required in a high-impact paper are all contributing factors.
The cost of this failure is high. As I have experienced at first hand as a researcher, attempts to reproduce others' published findings can be expensive and frustrating. Drug companies have spent vast amounts of time and money trying and failing to reproduce potential drug targets reported in the scientific literature - resources that should have contributed towards curing diseases.
Failed replications also quite often go unpublished, thereby leading others to repeat the same failed efforts...
No. Such decisions are made on the basis of clinical trials. You are talking about "research" which occurs long before clinical trials are done.
Yet, it is based on this largely private research that our political leaders are forming policy. For example, deciding whether to 'mandate' vaccination, what the "approved" medical treatment for a disease or condition will be, etc. Based on this research, insurance companies "decide" what medicines will be prescribed, and what treatments are "covered."
That's what I was thinking. I'm not sure what the rate of failure to replicate is in areas outside of medicine, but we've all heard of the famous cold fusion experiment as a famous example and that too was apparently a rush to publish on the part of Pons and Fleischman, rather than a measured approach to publishing good science.
Originally posted by Phage
Science requires replication of results.
Originally posted by Arbitrageur
But drugs that make it to market have a lot of data behind them, and even with all that work, some drugs still get pulled from the market when they get even more data from a larger population. So it shouldn't be too surprising that preliminary research based on a lot less data has more problems with replication.
More than half of biomedical findings cannot be reproduced..
I guess you missed the point of the article in your OP. It not about good science. It is about bad science. Research which is rushed to be published. The article is not about us being "sold" anything because what it is talking about never reaches us, beneficial or not.
It is difficult for me to understand the apparent confidence in what we are sold as science, when the odds are 50/50 or worse that they have actually practiced 'good science.'
There really is no profit involved with the shoddy research. Only wasted time. The article in the OP is about that wasted time and effort. That bad research detracts from good research because upon the application good science it is found to be lacking. That bad science benefits no one. Not the original researchers. Not the companies which see (at first look) a promising direction. Not the consumers.
But where profit is involved... how much weight does paltry scientific uncertainty hold with those who decide?
Drug companies have spent vast amounts of time and money trying and failing to reproduce potential drug targets reported in the scientific literature - resources that should have contributed towards curing diseases.
It comes as no surprise, then, that to survive in academia, let alone thrive, scientists must now game the system in ways that would have appalled our forebears. Outright fraud is just the tip the iceberg. Beneath it churns an ocean of dubious practices that spans the physical, biological and social sciences.
An unspoken rule among early-stage venture capital firms that “at least 50% of published studies, even those in top-tier academic journals, can't be repeated with the same conclusions by an industrial lab” has been recently reported (see Further information) and discussed
One classic example of this is the arguement about vaccines - where is the empirical evidence that shows researchers the results of double blind testing??? To my knowledge there are no such tests to be found in any archives.
I learned that there have been only three documented cases of autism within the Amish community - two of the Children were vaccinated and there was no information available regarding the third Child.
www.opposingviews.com...
From September 2008 to October 2009, 1899 Amish children were screened in the two Amish communities. A total of 25 children screened positive for ASD on either the SCQ or the DSM-IV-TR checklist. A total of 14 screened positive for ASD on both screeners. Of those 25 children, 14 were evaluated and seven children were confirmed as having a diagnosis of ASD using the ADI and/or ADOS, and clinical judgment. Interestingly, four of the seven only met ASD criteria on the ADOS but not the ADI. Three of the four who were not diagnosed by the ADI only missed criteria on the Behavioral Domain, which may be attributable to the reporting style of Amish caregivers.
Drug companies have spent vast amounts of time and money trying and failing to reproduce potential drug targets reported in the scientific literature - resources that should have contributed towards curing diseases.
The retracted studies aren't expected to affect the drugs' regulatory status because Dr. Reuben's studies weren't part of the packages that manufacturers submitted to the FDA or European authorities.